Zobrazeno 1 - 10
of 618
pro vyhledávání: '"Laura J, Esserman"'
Autor:
Heather I. Greenwood, Cristian K. Maldonado Rodas, Rita I. Freimanis, Alexa C. Glencer, Phoebe N. Miller, Rita A. Mukhtar, Case Brabham, Christina Yau, Jennifer M. Rosenbluth, Gillian L. Hirst, Michael J. Campbell, Alexander Borowsky, Nola Hylton, Laura J. Esserman, Amrita Basu
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract New approaches are needed to determine which ductal carcinoma in situ (DCIS) is at high risk for progression to invasive ductal carcinoma (IDC). We retrospectively studied DCIS patients who declined surgery (2002–2019), and received endocr
Externí odkaz:
https://doaj.org/article/1470ee587e164affa1e41c9b96a0b37b
Autor:
Yiwey Shieh, Jacquelyn Roger, Christina Yau, Denise M. Wolf, Gillian L. Hirst, Lamorna Brown Swigart, Scott Huntsman, Donglei Hu, Jovia L. Nierenberg, Pooja Middha, Rachel S. Heise, Yushu Shi, Linda Kachuri, Qianqian Zhu, Song Yao, Christine B. Ambrosone, Marilyn L. Kwan, Bette J. Caan, John S. Witte, Lawrence H. Kushi, Laura van ‘T Veer, Laura J. Esserman, Elad Ziv
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-11 (2023)
Abstract Aggressive breast cancers portend a poor prognosis, but current polygenic risk scores (PRSs) for breast cancer do not reliably predict aggressive cancers. Aggressiveness can be effectively recapitulated using tumor gene expression profiling.
Externí odkaz:
https://doaj.org/article/138d8faa316e4fb8af5632688f767d95
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-6 (2023)
Badal et al. outline principles that should be adopted during the development of artificial intelligence-based healthcare tools. These principles expand upon principles proposed by several organizations by emphasizing that AI be developed to improve
Externí odkaz:
https://doaj.org/article/3b1a8d28514647ffae071fcb1c8a1cc7
Autor:
Julie E. Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A. Parker, A. Jo Chien, Anne M. Wallace, Rashmi Murthy, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Rachel L. Yung, Claudine Isaacs, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Erica Stringer-Reasor, Elissa Price, Bonnie Joe, Minetta C. Liu, Lamorna Brown-Swigart, Emanuel F. Petricoin, Julia D. Wulfkuhle, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van ‘t Veer, Nola M. Hylton, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in
Externí odkaz:
https://doaj.org/article/f1ec1969e2aa401dafdcc1102c26a20e
Autor:
Joyce V. Lee, Filomena Housley, Christina Yau, Rachel Nakagawa, Juliane Winkler, Johanna M. Anttila, Pauliina M. Munne, Mariel Savelius, Kathleen E. Houlahan, Daniel Van de Mark, Golzar Hemmati, Grace A. Hernandez, Yibing Zhang, Susan Samson, Carole Baas, Laura J. Esserman, Laura J. van ‘t Veer, Hope S. Rugo, Christina Curtis, Juha Klefström, Mehrdad Matloubian, Andrei Goga
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
The oncoprotein c-Myc is often overexpressed in triple negative breast cancer and has a role in tumor progression and resistance to therapy. Here the authors show that elevated MYC expression is correlated with low immune infiltration, diminished MHC
Externí odkaz:
https://doaj.org/article/5ba305a5a1f9497c9247af3f00c75bef
Autor:
Nu N. Le, Wen Li, Natsuko Onishi, David C. Newitt, Jessica E. Gibbs, Lisa J. Wilmes, John Kornak, Savannah C. Partridge, Barbara LeStage, Elissa R. Price, Bonnie N. Joe, Laura J. Esserman, Nola M. Hylton
Publikováno v:
Tomography, Vol 8, Iss 3, Pp 1208-1220 (2022)
This study evaluated the inter-reader agreement of tumor apparent diffusion coefficient (ADC) measurements performed on breast diffusion-weighted imaging (DWI) for assessing treatment response in a multi-center clinical trial of neoadjuvant chemother
Externí odkaz:
https://doaj.org/article/4e753dc001e14a2996cd0448e63b5a67
Autor:
Laura L. Barnes, MD, Rob Foster, MD, Rita A. Mukhtar, MD, Laura J. Esserman, MD, MBA, Cheryl Ewing, MD, Michael Alvarado, MD, Jasmine Wong, MD, Merisa Piper, MD
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 11, Iss 1, p e4767 (2023)
Background:. Development of the nipple-sparing mastectomy (NSM) technique has dramatically improved breast reconstruction, and preservation of the nipple–areolar complex (NAC) positively influences patient satisfaction. However, women with large, p
Externí odkaz:
https://doaj.org/article/a8eabbd7c3824658bc9176f415a22070
Autor:
Daniela Nachmanson, Adam Officer, Hidetoshi Mori, Jonathan Gordon, Mark F. Evans, Joseph Steward, Huazhen Yao, Thomas O’Keefe, Farnaz Hasteh, Gary S. Stein, Kristen Jepsen, Donald L. Weaver, Gillian L. Hirst, Brian L. Sprague, Laura J. Esserman, Alexander D. Borowsky, Janet L. Stein, Olivier Harismendy
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-13 (2022)
Abstract Microenvironmental and molecular factors mediating the progression of Breast Ductal Carcinoma In Situ (DCIS) are not well understood, impeding the development of prevention strategies and the safe testing of treatment de-escalation. We addre
Externí odkaz:
https://doaj.org/article/25a046ee37fb400db82cd80023557ef6
Autor:
Mary Kathryn Abel, Amy M. Shui, Michelle Melisko, A. Jo Chien, Emi J. Yoshida, Elizabeth M. Lancaster, Laura Van ‘T Veer, Laura J. Esserman, Rita A. Mukhtar
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract When molecular testing classifies breast tumors as low risk but clinical risk is high, the optimal management strategy is unknown. One group of patients who may be more likely to have such discordant risk are those with invasive lobular carc
Externí odkaz:
https://doaj.org/article/b88c275529fe4c4da1b6cfc8c63c7d7e
Autor:
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pert
Externí odkaz:
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1